A STUDY ON THE EFFICIENCY OF LOW COST VERMICOMPOSTING STRUCTURE

The present study was conducted at the Dryland Technology Park ,All India Coordinated Research Project for Dryland Agriculture, Biswanath Chariali Center, Biswanath College of Agriculture, Assam Agricultural University, Biswanath Chariali, District sonitpur Assam, India during 2012 -2013 with the objective to find out the efficiency of the low cost vermicomposting unit as compared to conventional units involving higher cost of construction. The experiment was laid out in a randomized block design (RBD) with 4 treatments i.e T1: Vermicomposting with Perionyx excavates in concrete pits (Control) with dimension 2.5 m(L) X 0.91 m (B) X 0.91 m(D),T2: Vermicomposting with Perionyx excavates in low cost vermicomposting unit with dimension of 2.5 m(L) X 0.91 m (B) X 0.91 m(D),T3: Vermicomposting with Perionyx excavates in low cost vermicomposting unit with dimension of 2.5 m(L) X 1.2 m (B) X 0.76 m(D),T4: Vermicomposting with Perionyx excavates in low cost vermicomposting unit with dimension 2.5 m(L) X 1.2 m (B) X 0.46 m(D) replicated five times. Among the 4 treatments T1 ,T2 and T3 was found to be at par in terms of quantity of vermicompost harvested. Result revealed that among the different low cost vermicomposting units T2 was efficient in terms of quantity of vemicompost harvested, vermiworms and numbers of cocoons produced followed by T3. Production of vermiwash was highest in T1 (12 to 10 L per week) followed by T2(10 to 9 L per week). Daily temperature recorded in the vermi composting tanks was initially higher and gradually decreased with the decomposition process. Benefit: Cost ratio was highest in T2 ( 6.56:1)followed by T3(4.46:1)

Dasatinib in pediatric patients with chronic myeloid leukemia in chronic phase:results from a phase II trial

PurposeSafe, effective treatments are needed for pediatric patients with chronic myeloid leukemia in chronic phase (CML-CP). Dasatinib is approved for treatment of adults and children with CML-CP. A phase I study determined suitable dosing for children with Philadelphia chromosome-positive (Ph+) leukemias.MethodsCA180-226/NCT00777036 is a phase II, open-label, nonrandomized prospective trial of patients < 18 years of age receiving dasatinib. There are three cohorts: (1) imatinib-resistant/intolerant CML-CP, (2) imatinib-resistant/intolerant CML in accelerated/blast phase or Ph+ acute lymphoblastic leukemia (n = 17), and (3) newly diagnosed CML-CP treated with tablets or powder for oral suspension. Major cytogenetic response > 30% for imatinib-resistant/intolerant patients and complete cytogenetic response (CCyR) > 55% for newly diagnosed patients were of clinical interest.ResultsOf 113 patients with CML-CP, 14 (48%) who were imatinib-resistant/intolerant and 61 (73%) who were newly diagnosed remained on treatment at time of analysis. Major cytogenetic response > 30% was reached by 3 months in the imatinib-resistant/intolerant group and CCyR > 55% was reached by 6 months in the newly diagnosed CML-CP group. CCyR and major molecular response by 12 months, respectively, were 76% and 41% in the imatinib-resistant/intolerant group and 92% and 52% in newly diagnosed CML-CP group. Progression-free survival by 48 months was 78% and 93% in the imatinib-resistant/intolerant and newly diagnosed CML-CP groups, respectively. No dasatinib-related pleural or pericardial effusion, pulmonary edema, or pulmonary arterial hypertension were reported. Bone growth and development events were reported in 4% of patients.ConclusionIn the largest prospective trial to date in children with CML-CP, we demonstrate that dasatinib is a safe, effective treatment of pediatric CML-CP. Target responses to first- or second-line dasatinib were met early, and deep molecular responses were observed. Safety of dasatinib in pediatric patients was similar to that observed in adults; however, no cases of pleural or pericardial effusion or pulmonary arterial hypertension were reported

Emergence of an unrelated highly aberrant clone in an AML patient at relapse four months after peripheral blood stem cell transplantation

We report a case of AML-M1 with 5q aberration at diagnosis. The patient was treated with high-dose chemotherapy (HDCT). After remission induction, he received allogenic peripheral blood stem cell transplantation (PBSCT) from an HLA-match donor brother. The successive follow-up conventional cytogenetics investigations in remission after HDCT and PBSCT revealed cytogenetic remission. The most interesting observation in this case is that relapsed marrow revealed the emergence of an entirely new, highly aberrant, unrelated clone with unusual translocations t(6;17)(p23;p11.2),+8,der(8)dup inv(8)(q23qter), t(10;19)(q26;q13.3) 4½ months after PBSCT. Our findings suggest the possibility of a mutagenic effect of HDCT and myeloablative intense chemotherapy before PBSCT that could have induced a genetic lesion in the recipient's genetically unstable stem cells in an environment of immunosuppression. The highly complex nature of the clone and the rapid clonal evolution indicates the possibility of selective pressure with proliferative advantage

Developing novel bacterial based bioformulation having PGPR properties for enhanced production of agricultural crops

56-60Plant growth promoting rhizobacteria (PGPR) are beneficial rhizobacteria which enhance plant growth as well as the productivity by a variety of mechanisms. PGPR were isolated from the rhizosphere region of som plants (<i style="mso-bidi-font-style: normal">Machilus bombycina King) maintained at the Central Muga Eri Research and Training Institute, Lahdoigarh, Jorhat. A bacterial based bioformulation was prepared and sprayed over the experimental crops including tomato (Solanum lycopersicum), cauliflower (Brassica oleracea var botrytis), chili (Capsicum annuum) and brinjal (Solanum <i style="mso-bidi-font-style: normal">melongena). Biochemical analysis was done on these PGPR treated crops as well as the untreated crops. The bioformulations prepared from Bacillus cereus (MTCC 8297), Pseudomonas rhodesiae (MTCC 8299) and Pseudomonas rhodesiae (MTCC 8300) was found to be the most effective in increasing the shoot height, number of leaves, early fruiting and total biomass content of the plants after treatment

Consensus in the management of multiple myeloma in India at myeloma state of the art 2016 conference

The science of multiple myeloma (MM) and related plasma cell disorders is rapidly evolving with increased understanding of the disease biology and recent approval of the newer drugs widening the therapeutic armamentarium. Despite multiple international guidelines regarding the management of this disease, the practice of managing MM is not uniform amongst Indian physicians. There are challenges in management which are unique to the Indian patients. This review discusses these challenges and the consensus of the nation-wide experts in dealing with the same. We also briefly highlighted the perspective of international experts as discussed in the Myeloma State of the Art conference held in September 2016 at PGI, Chandigarh. An Indian Myeloma Academic Groupe (IMAGe) group was formed to strengthen the research, create awareness about myeloma and related disorders and form consensus guidelines/ recommendations that can be adapted to the Indian Scenario